1
|
Tatano Y, Shimizu T, Sano C, Tomioka H. Roles of autophagy in killing of mycobacterial pathogens by host macrophages - Effects of some medicinal plants. Eur J Microbiol Immunol (Bp) 2024; 14:26-36. [PMID: 38349363 PMCID: PMC10895364 DOI: 10.1556/1886.2023.00062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Accepted: 01/29/2024] [Indexed: 02/24/2024] Open
Abstract
Autophagy is a cellular stress-induced intracellular process, through which damaged cellular components are decomposed via lysosomal degradation. This process plays important roles in host innate immunity, particularly the elimination of intracellular pathogens inside host macrophages. A more detailed understanding of the roles of autophagic events in the effective manifestation of macrophagic antimycobacterial activity is needed. Furthermore, the effects of medicinal plants on macrophagic autophagy response to mycobacterial infection need to be clarified. We herein examined the significance of autophagic events in the manifestation of host immunity during mycobacterial infection, by performing a literature search using PubMed. Recent studies demonstrated that autophagy up-regulated macrophage functions related to the intracellular killing of mycobacteria, even when pathogens were residing within the cytoplasm of macrophages. The majority of medicinal plants potentiated macrophagic autophagy, thereby enhancing their antimycobacterial functions. In contrast, most medicinal plants down-regulate the development and activation of the Th17 cell population, which reduces macrophage antimycobacterial activity. These opposing effects of medicinal plants on macrophage autophagy (enhancement) and Th17 cell functions (inhibition) may provide a plausible explanation for the clinical observation of their modest efficacy in the treatment of mycobacterial infections.
Collapse
Affiliation(s)
- Yutaka Tatano
- 1Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan
| | - Toshiaki Shimizu
- 2Department of Nutrition Administration, Yasuda Women's University, Hiroshima, Japan
| | - Chiaki Sano
- 3Department of Community Medicine Management, Faculty of Medicine, Shimane University, Izumo Japan
| | | |
Collapse
|
2
|
Miwa Y, Tomioka H, Hosaka M, Mitamura Y. POS0586 DIAGNOSIS OF MENTAL DISORDER COMPLICATED BY RHEUMATOID ARTHRITIS: A STUDY OF THE VALIDITY OF A PSYCHIATRIST’S DIAGNOSIS AND QUESTIONNAIRE METHOD. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundIt has been reported that about 15% of patients with rheumatoid arthritis (RA) have depression, and most of these studies have used questionnaire methods. Most of the studies have used questionnaires for depression. Because the depression questionnaire includes questions about physical symptoms, it is necessary to be careful in interpreting the results when there is an underlying disease. In addition, there are no studies on other mental disorders.ObjectivesIn this study, we examined the validity of the questionnaire method for the diagnosis of RA complicated by psychiatric disorders.MethodsForty-nine outpatients with RA who agreed to participate in this study were included. Age, gender, type of Disease-modifying anti-rheumatic drugs, prednisolone use, presence of diabetes, hypertension, dyslipidemia, and CRP were investigated. The Patient Health Questionnaire-9 (PHQ-9) and Center for Epidemiologic Studies Depression Scale (CES-D) questionnaires were used; a score of 10 or more on the PHQ-9 and 16 or more on the CES-D was considered a cutoff. The psychiatrist was blinded to the results of the questionnaire and conducted a structured interview in a separate room. The psychiatrist’s diagnosis was defined as the Gold Standard, and was compared with the PHQ-9 and CES-D.ResultsPsychiatrist’s diagnosis was abnormal in 9 patients. This included one patient with major depression, one patient with moderate depression, two patients with minor depression, and two patients with adjustment disorder. The PHQ-9 had a specificity of 98%, a sensitivity of 33%, a positive predictive value of 75%, and a negative predictive value of 87%. The CES-D had a specificity of 82%, a sensitivity of 100%, a positive predictive value of 56%, and a negative predictive value of 100%.ConclusionThe PHQ-9 and CES-D may be useful in screening for psychiatric disorders including associated with RA.Disclosure of InterestsNone declared.
Collapse
|
3
|
Affiliation(s)
- Haruaki Tomioka
- Yasuda Women's University Shimane University School of Medicine, Japan
| |
Collapse
|
4
|
Tomioka H, Tatano Y, Shimizu T, Sano C. Immunoadjunctive Therapy against Bacterial Infections Using Herbal Medicines Based on Th17 Cell-mediated Protective Immunity. Curr Pharm Des 2021; 27:3949-3962. [PMID: 34102961 DOI: 10.2174/1381612827666210608143449] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Accepted: 04/27/2021] [Indexed: 11/22/2022]
Abstract
One of the major health concerns in the world is the global increase in intractable bacterial infectious diseases due to the emergence of multi- and extensively drug-resistant bacterial pathogens as well as an increase in compromised hosts around the world. Particularly, in the case of mycobacteriosis, the high incidence of tuberculosis in developing countries, resurgence of tuberculosis in industrialized countries, and increase in the prevalence of Mycobacterium avium complex infections are important worldwide health concerns. However, the development of novel antimycobacterial drugs is currently making slow progress. Therefore, it is considered that devising improved administration protocols for clinical treatment against refractory mycobacteriosis using existing chemotherapeutics is more practical than awaiting the development of new antimycobacterial drugs. The regulation of host immune responses using immunoadjunctive agents may increase the efficacy of antimicrobial treatment against mycobacteriosis. The same situations also exist in cases of intractable infectious diseases due to common bacteria other than mycobacteria. The mild and long-term up-regulation of host immune reactions in hosts with intractable chronic bacterial infections, using herbal medicines and medicinal plants, may be beneficial for such immunoadjunctive therapy. This review describes the current status regarding basic and clinical studies on therapeutic regimens using herbal medicines, useful for the clinical treatment of patients with intractable bacterial infections. In particular, we focus on immunoadjunctive effects of herbal medicines on the establishment and manifestation of host antibacterial immunity related to the immunological roles of Th17 cell lineages.
Collapse
Affiliation(s)
- Haruaki Tomioka
- Department of Basic Medical Science for Nursing, Department of Contemporary Psychology, Yasuda Women's University, Hiroshima, Japan
| | - Yutaka Tatano
- Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan
| | - Toshiaki Shimizu
- Department of Nutrition Administration, Yasuda Women's University, Hiroshima,, Japan
| | - Chiaki Sano
- Department of Community Medicine Management, Shimane University School of Medicine, Izumo, Japan
| |
Collapse
|
5
|
Nunoya T, Omori T, Tomioka H, Umeda F, Suzuki T, Uetsuka K. Intracellular Localization of Mycoplasma bovis in the Bronchiolar Epithelium of Experimentally Infected Calves. J Comp Pathol 2020; 176:14-18. [PMID: 32359627 DOI: 10.1016/j.jcpa.2020.01.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2019] [Revised: 01/17/2020] [Accepted: 01/23/2020] [Indexed: 11/29/2022]
Abstract
Lung tissues from calves infected experimentally with Mycoplasma bovis were examined by immunohistochemistry and electron microscopy. All inoculated calves had dark red areas of consolidation affecting both left and right lungs, which were characterized microscopically by subacute purulent bronchiolitis with hyperplasia of the surrounding lymphoid tissue. Immunohistochemically, M. bovis antigen was detected on the surface and inside the cytoplasm of bronchiolar epithelial cells in the pneumonic foci. The antigen was also found in the cytoplasm of phagocytes at the margin of bronchiolar exudates. Electron microscopically, numerous organisms were demonstrated in the immunohistochemically-positive sites. These findings suggest that M. bovis organisms adhere to the bronchiolar epithelium and at least some of them invade the epithelium.
Collapse
Affiliation(s)
- T Nunoya
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo, Japan.
| | - T Omori
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo, Japan
| | - H Tomioka
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo, Japan
| | - F Umeda
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo, Japan
| | - T Suzuki
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo, Japan
| | - K Uetsuka
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo, Japan; Laboratory of Animal Health and Hygiene, Department of Food and Life Sciences, College of Agriculture, Ibaraki University, 3-21-1 Chuuo, Ami, Inashiki, Ibaraki, Japan
| |
Collapse
|
6
|
Tomioka H, Tatano Y, Shimizu T, Sano C. Clinical and Basic Studies on Therapeutic Efficacy of Herbal Medicines against Mycobacterial Infections. Medicines (Basel) 2019; 6:medicines6020067. [PMID: 31248144 PMCID: PMC6630501 DOI: 10.3390/medicines6020067] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Revised: 06/13/2019] [Accepted: 06/14/2019] [Indexed: 02/07/2023]
Abstract
The high incidence of tuberculosis (TB) in developing countries, the resurgence of TB in industrialized countries, and the worldwide increase in the prevalence of Mycobacterium avium complex infections are important global health concerns. However, the development of novel antimycobacterial drugs is currently making very slow progress. Therefore, it is considered that devising improved administration protocols for clinical treatment against intractable mycobacteriosis using existing chemotherapeutics is more practical than awaiting the development of new antimycobacterial drugs. The regulation of host immune responses using immunoadjunctive agents may increase the efficacy of antimicrobial treatment against mycobacteriosis. In particular, the mild and long-term up-regulation of host immune reactions against mycobacterial pathogens using herbal medicines may be beneficial for such immunoadjunctive therapy. This review focuses on the current status regarding basic and clinical studies on protocols using herbal medicines, including medicinal plants, useful for the clinical treatment of intractable mycobacterial infections.
Collapse
Affiliation(s)
- Haruaki Tomioka
- Department of Basic Medical Science for Nursing, Department of Primary Education, Yasuda Women's University, Hiroshima 731-0153, Japan.
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo 693-8501, Japan.
| | - Yutaka Tatano
- Department of Pharmaceutical Sciences, International University of Health and Welfare, Otawara 324-8501, Japan.
| | - Toshiaki Shimizu
- Department of Nutritional Sciences, Yasuda Women's University, Hiroshima 731-0153, Japan.
| | - Chiaki Sano
- Department of Community Medicine Management, Shimane University School of Medicine, Izumo 693-8501, Japan.
| |
Collapse
|
7
|
Kanehiro Y, Tomioka H, Pieters J, Tatano Y, Kim H, Iizasa H, Yoshiyama H. Identification of Novel Mycobacterial Inhibitors Against Mycobacterial Protein Kinase G. Front Microbiol 2018; 9:1517. [PMID: 30050511 PMCID: PMC6052090 DOI: 10.3389/fmicb.2018.01517] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Accepted: 06/18/2018] [Indexed: 02/01/2023] Open
Abstract
Protein kinase G (PknG) is a eukaryotic-like serine/threonine kinase that is expressed by Mycobacterium tuberculosis and promotes survival of mycobacteria in host macrophages by suppressing phagosome-lysosome fusion. Thus, compounds showing inhibitory activity against PknG are promising anti-mycobacterial agents. We therefore aimed to develop anti-mycobacterial agents by identifying new PknG inhibitors. A luciferase-based PknG kinase assay was used to screen potential inhibitors of PknG. We found that four compounds, namely AZD7762, R406, R406-free base, and CYC116, inhibited PknG activities. AZD7762, R406, and R406-free base promoted transfer of mycobacteria to lysosomes. These compounds also inhibited survival of M. bovis Bacillus Calmette–Guérin (BCG) inside human macrophages. Furthermore, R406 and R406-free base showed bactericidal activity against BCG in infected human macrophages without cytotoxicity. The PknG inhibitors identified in this study by the luciferase-based PknG kinase assay may be promising leads for the development of anti-mycobacterial agents.
Collapse
Affiliation(s)
- Yuichi Kanehiro
- Department of Microbiology, Faculty of Medicine, Shimane University, Izumo, Japan
| | - Haruaki Tomioka
- Department of Basic Medical Sciences for Nursing, Yasuda Women's University, Hiroshima, Japan
| | - Jean Pieters
- Biozentrum, University of Basel, Basel, Switzerland
| | - Yutaka Tatano
- Department of Pharmaceutical Science, International University of Health and Welfare, Ohtawara, Japan
| | - Hyoji Kim
- Department of Microbiology, Faculty of Medicine, Shimane University, Izumo, Japan
| | - Hisashi Iizasa
- Department of Microbiology, Faculty of Medicine, Shimane University, Izumo, Japan
| | - Hironori Yoshiyama
- Department of Microbiology, Faculty of Medicine, Shimane University, Izumo, Japan
| |
Collapse
|
8
|
Abstract
The high incidence of tuberculosis (TB) in developing countries, the resurgence of TB in industrialized countries, and the worldwide increase in the prevalence of Mycobacterium avium complex infections have prompted the quest for new antimycobacterial drugs. However, the development of such chemotherapeutics is currently making very slow progress. It therefore appears that devising improved administration protocols for clinical treatment against intractable mycobacteriosis using existing chemotherapeutics is more practical than awaiting the development of novel antimycobacterial drugs. The modulation of host immune responses using immunoadjunctive agents may increase the efficacy of antimicrobial treatment against mycobacteriosis. Particularly, the mild and long-term up-regulation of host immune reactions against mycobacterial pathogens using Chinese herbal medicines (CHMs) may be beneficial for immunoadjunctive therapy. This review focuses on the current status and future prospects regarding the development of CHMs that can be useful for the clinical control of intractable mycobacterial infections.
Collapse
Affiliation(s)
- Haruaki Tomioka
- 1 Department of Basic Medical Science for Nursing, Department of Primary Education, Yasuda Women's University, Hiroshima, Japan.,2 Shimane University School of Medicine, Izumo, Shimane, Japan
| |
Collapse
|
9
|
Tomioka H, Sano C, Tatano Y. Host-Directed Therapeutics against Mycobacterial Infections. Curr Pharm Des 2017; 23:2644-2656. [DOI: 10.2174/1381612822666161202121550] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Accepted: 10/12/2016] [Indexed: 11/22/2022]
Affiliation(s)
- Haruaki Tomioka
- Department of Basic Medical Science for Nursing, Department of Primary Education, Yasuda Women’s University, Hiroshima, Hiroshima 731-0153, Japan
| | - Chiaki Sano
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693-8501, Japan
| | - Yutaka Tatano
- Department of Pharmaceutical Sciences, International University of Health and Welfare, Ohtawara, Tochigi 324-8501, Japan
| |
Collapse
|
10
|
Tatano Y, Tomioka H. [Unique macrophages induced by infection with Mycobacterium avium complex regulate the mitogenesis and differentiation of T cells]. Seikagaku 2016; 88:660-663. [PMID: 29624338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
|
11
|
Shimizu T, Tatano Y, Tomioka H. Aldose reductase participates in the downregulation of T cell functions due to suppressor macrophages. Sci Rep 2016; 6:21093. [PMID: 26868163 PMCID: PMC4751572 DOI: 10.1038/srep21093] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Accepted: 01/15/2016] [Indexed: 02/06/2023] Open
Abstract
The cell-to-cell contact of T lymphocytes with immunosuppressive macrophages causes marked changes in the tyrosine phosphorylation of some cytosolic proteins of T cells. By phosphoproteome analysis, we identified a 36-kDa protein as aldose reductase (AR). The AR expression in T cells was not changed by TCR stimulation or due to cell-to-cell transmission of suppressor signals from immunosuppressive macrophages. Therefore, AR phosphorylation/dephosphorylation is essential for the transduction of TCR-mediated T-cell stimulatory signals, and moreover plays important roles for the cross-talk of immunosuppressive macrophage-derived suppressor signals with the signaling pathways for T-cell activation. Moreover, AR played important roles in the upregulation of ERK1/2-mediated signaling pathways in T lymphocytes. Notably, the enzymatic activity of AR was not required for its signaling action. Taken together, it is concluded that AR mediates intracellular transmission of the suppressor signal of immunosuppressive macrophages toward downstream ERK1/2 pathways, possibly through its direct interaction with acceptor proteins.
Collapse
Affiliation(s)
- Toshiaki Shimizu
- Department of Nutritional Sciences, Yasuda Women's University, Hiroshima 731-0153, Japan
| | - Yutaka Tatano
- Department of Pharmaceutical Sciences, International University of Health and Welfare, Ohtawara 324-8501, Japan
| | - Haruaki Tomioka
- Department of Basic Medical Sciences for Nursing, Yasuda Women's University, Hiroshima 731-0153, Japan.,Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo 693-8501, Japan
| |
Collapse
|
12
|
Tomioka H, Tatano Y, Sano C, Shimizu T. [M1 AND M2 MACROPHAGE POPULATIONS: THOSE INDUCED AND ACTIVATED BY MYCOBACTERIAL INFECTIONS]. Kekkaku 2016; 91:75-82. [PMID: 27263230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
In the advanced stages of mycobacterial infections, host immune systems tend to change from a Th1-type to Th2-type immune response, resulting in the abrogation of Th1 cell- and macrophage-mediated antimicrobial host protective immunity. Notably, this type of immune conversion is occasionally associated with the generation of. certain types of suppressor macrophage populations. During the course of infections due to pathogenic mycobacteria, the generation of macrophages which possess strong suppressor activity against host T- and B-cell functions is frequently encountered. This review describes the immunological properties of M1- and M2-type macrophages generated in hosts with certain microbial infections including mycobacteriosis and those generated in tumor-bearing animals. Particularly, this paper highlights the immunological and molecular biological characteristics of M1 and M2 macrophage populations, which are induced by mycobacterial infections
Collapse
|
13
|
Tomioka H. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Curr Pharm Des 2015; 20:4305-6. [PMID: 24245755 DOI: 10.2174/1381612819666131118203915] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Worldwide, tuberculosis (TB) remains the most frequent and important infectious disease causing morbidity and death. However, the development of new drugs for the treatment and prophylaxis of TB, particularly those truly active against dormant and persistent types of tubercle bacilli, has been slow, although some promising drugs, such as diarylquinoline TMC207, nitroimidazopyran PA-824, nitroimidazo-oxazole Delamanid (OPC-67683), oxazolidinone PNU-100480, ethylene diamine SQ-109, and pyrrole derivative LL3858, are currently under phase 1 to 3 clinical trials. Therefore, novel types of antituberculous drug, which act on unique drug targets in Mycobacterium tuberculosis (MTB) pathogens, particularly drug targets related to the establishment of mycobacterial dormancy in the host's macrophages, are urgently needed. In this context, it should be noted that current anti-TB drugs mostly target the metabolic reactions and proteins which are essential for the growth of MTB in extracellular milieus. It may also be promising to develop another type of drug that exerts an inhibitory action against bacterial virulence factors which cross-talk and interfere with signaling pathways of MTB-infected immunocompetent host cells, such as lymphocytes, macrophages, and NK cells, thereby changing the intracellular milieus that are favorable to intramacrophage survival and the growth of infected bacilli. This special issue contains ten review articles, dealing with recent approaches to identify and establish novel drug targets in MTB for the development of new and unique antitubercular drugs, including those related to mycobacterial dormancy and crosstalk with cellular signaling pathways. In addition, this special issue contains some review papers with special reference to the drug design based on quantitative structure-activity relationship (QSAR) analysis, especially three-dimensional (3D)-QSAR. New, critical information on the entire genome of MTB and mycobacterial virulence genes is promoting the elucidation of the molecular structures of drug targets in MTB, and are consequently markedly useful for the design of new, promising antituberculous drugs using QSAR techniques. In this issue, we review the following areas. Firstly, Dr. Li M. Fu reviews the perspective that combines machine learning and genomics for drug discovery in tuberculosis, in relation to the problem that the exhaustive search for useful drug targets over the entire MTB genome would not be as productive as expected in practice [1]. Secondly, the review article by Drs. R. S. Chauhan. S. K. Chanumolu, C. Rout, and R. Shrivastava focuses on analysis of the current state of MTB genomic resources, host-pathogen interaction studies in the context of mycobacterial persistence, and drug target discovery based on the utilization of computational tools and metabolic network analyses [2]. Thirdly, Drs. Daria Bottai, Agnese Serafini, Alessandro Cascioferro, Roland Brosch, and Riccardo Manganelli review the current knowledge on MTB T7SS/ESX secretion systems and their impact on MTB physiology and virulence, and the possible approaches to develop T7SS/ESX inhibitors [3]. Fourthly, Drs. E. Jeffrey North, Mary Jackson, and Richard E. Lee review and analyze new and emerging inhibitors of the mycolic acid biosynthetic pathway, including mycobacterial enzymes for fatty acid synthesis, mycolic acid-modifying enzymes, fatty acid-activating and -condensing enzymes, transporters, and transferases, that have been discovered in the post-genomic era of tuberculosis drug discovery [4]. Fifthly, Drs. Katarina Mikusova, Vadim Makarov, and Joao Neres review the mycobacterial enzyme DprE1, which catalyzes a unique epimerization reaction in the biosynthesis of decaprenylphosphoryl arabinose, a single donor of the arabinosyl residue for the build-up of arabinans, one of the mycobacterial cell wall components, as an important drug target especially for the development of benzothiazinones [5]. Sixthly, I review the present status of global research on novel drug targets related to the Toll-like receptor in the MTB pathogen, with special reference to mycobacterial virulence factors that cross-talk and interfere with signaling pathways of host macrophages [6]. The following four review articles deal with drug design of novel anti-TB agents employing QSAR techniques. Firstly, Drs. Nidhi and Mohammad Imran Siddiqi review 2D and 3D QSAR approaches and the recent trends of these methods integrated with virtual screening using the 3D pharmacophore and molecular docking approaches for the identification and design of novel antituberculous agents, by presenting a comprehensive overview of QSAR studies reported for newer antituberculous agents [7]. Secondly, Drs. Filomena Martins, Cristina Ventura, Susana Santos, and Miguel Viveiros review the current status of different QSAR-based strategies for the design of novel anti-TB drugs based upon the most active anti-TB agent, isoniazid, from the viewpoint of the development of promising derivatives that are active against isoniazid- resistant strains with katG mutations [8]. Thirdly, Drs. Sanchaita Rajkhowa and Ramesh C. Deka review current studies concerning 2D and 3D QSAR models that contain density-functional theory (DFT)-based descriptors as their parameters [9]. Notably, DFT-based descriptors such as atomic charges, molecular orbital energies, frontier orbital densities, and atom-atom polarizabilities are very useful in predicting the reactivity of atoms in molecules. Fourthly, Drs. Renata V. Bueno, Rodolpho C. Braga, Natanael D. Segretti, Elizabeth I. Ferreira, Gustavo H. G. Trossini, and Carolina H. Andrade review the current progress and applications of QSAR analysis for the discovery of innovative tuberculostatic agents as inhibitors of ribonucleotide reductase, DNA gyrase, ATP synthase, and thymidylate kinase enzymes, highlighting present challenges and new opportunities in TB drug design [10]. The aim of this issue is to address the future prospects for the development of new antituberculous drugs. There are a number of difficulties in computational drug-design for the development of new drug formulations with potential antimycobacterial effects, especially therapeutic and prophylactic efficacy against infection due to dormant-type MTB pathogens. In addition, it should be emphasized that the most urgent goal of TB chemotherapy is develop highly active, low-cost drugs which can be used not only in industrialized but also in developing countries, because most global TB incidence occurs in the latter. I am sincerely grateful to the individuals who contributed to this work. All authors are experts in their fields and they made earnest efforts to perform these in-depth reviews. I thank them all.
Collapse
Affiliation(s)
- Haruaki Tomioka
- Department of Microbiology and Immunology Shimane University School of Medicine Izumo, Shimane 693-8501 Japan.
| |
Collapse
|
14
|
Tatano Y, Shimizu T, Tomioka H. Unique macrophages different from M1/M2 macrophages inhibit T cell mitogenesis while upregulating Th17 polarization. Sci Rep 2014; 4:4146. [PMID: 24553452 PMCID: PMC3930092 DOI: 10.1038/srep04146] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Accepted: 02/05/2014] [Indexed: 02/06/2023] Open
Abstract
Mycobacterial infection induces suppressor macrophages (MΦs), causing disease exacerbation. There are two major MΦ subsets (M1 and M2 MΦs) that are phenotypically and functionally different. Here, we examined which of the MΦ subsets the mycobacterial infection-induced suppressor MΦs (MIS-MΦs) belong to. MIS-MΦs down-regulated T cell production of Th1 and Th2 cytokines but markedly increased production of interleukin (IL)-17A and IL-22 through up-regulation of Th17 cell expansion. In this phenomenon, a novel MΦ population, which is functionally distinguishable from M1 and M2 MΦ subsets and possesses unique phenotypes (IL-12(+), IL-1β(high), IL-6(+), tumor necrosis factor (TNF)-α(+), nitric oxide synthase (NOS) 2(+), CCR7(high), IL-10(high), arginase (Arg)-1(-), mannose receptor (MR)(low), Ym1(high), Fizz(low), and CD163(high)), played central roles through the action of IL-6 and transforming growth factor (TGF)-β but not IL-21 and IL-23. This new type of MΦ population was induced in infected mice and actively supported the in vivo expansion of Th17 cells.
Collapse
Affiliation(s)
- Yutaka Tatano
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693-8501, Japan
| | - Toshiaki Shimizu
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693-8501, Japan
| | - Haruaki Tomioka
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693-8501, Japan
| |
Collapse
|
15
|
Tomioka H, Tatano Y, Yasumoto K, Shimizu T. Recent advances in antituberculous drug development and novel drug targets. Expert Rev Respir Med 2014; 2:455-71. [DOI: 10.1586/17476348.2.4.455] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
16
|
Tomioka H. New Approaches to Tuberculosis - Novel Drugs Based on Drug Targets Related to Toll-Like Receptors in Macrophages. Curr Pharm Des 2013; 20:4404-17. [DOI: 10.2174/1381612819666131118163331] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2013] [Accepted: 11/04/2013] [Indexed: 11/22/2022]
|
17
|
Sato K, Shimizu T, Dimova V, Tomioka H. Antimicrobial Activities of Cinnamyl Rifamycin Derivatives, T-9 and T-11, againstMycobacterium tuberculosisandMycobacterium aviumComplex (MAC) with Special Reference to the Activities against Intracellular MAC. Microbiol Immunol 2013; 50:621-3. [PMID: 16924146 DOI: 10.1111/j.1348-0421.2006.tb03836.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The mycobacterial activities of cinamyl rifamycin derivatives, T-9 and T-11, especially against extracellular and intracellular Mycobacterium avium complex residing within macrophages and type II pneumocytes were compared with those of other rifamycins. The activities of test rifamycins were found to be in the order rifalazil, rifabutin, T-9, T-11, and rifampicin.
Collapse
Affiliation(s)
- Katsumasa Sato
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane, Japan
| | | | | | | |
Collapse
|
18
|
Shimada T, Kiyota N, Imamura Y, Nishimura M, Funakoshi Y, Tomioka H, Toyoda M, Chayahara N, Mukohara T, Minami H. Safety Profile of Chemotherapy with Docetaxel and Cisplatin for Recurrent or Metastatic Head and Neck Cancer. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Toyoda M, Imamura Y, Nishimura M, Funakoshi Y, Tomioka H, Shimada T, Chayahara N, Kiyota N, Mukohara T, Minami H. Retrospective Analysis of Renal Function in Patients with Advanced Biliary Tract Cancer Treated by GC. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Funakoshi Y, Mukohara T, Tomioka H, Ekyalongo R, Kataoka Y, Inui Y, Kawamori Y, Kiyota N, Fujiwara Y, Minami H. 306 Excessive MET Signaling Causes Acquired Resistance to and Addiction to MET Inhibitors in MKN45 Gastric Cancer Cell Line. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72104-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
21
|
Kataoka T, Kiyota N, Shimada T, Imamura Y, Chayahara N, Toyoda M, Funakoshi Y, Tomioka H, Fujiwara Y, Nibu K, Komori T, Nishimura H, Sasaki R, Mukohara T, Minami H. A Pilot Randomized Trial Comparing Standard Pain Control with or without Gabapentin for the Treatment of Pain Related to Radiation-Induced Mucositis in Head and Neck Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32221-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
22
|
Fujiwara Y, Chayahara N, Kiyota N, Nakano K, Mukohara T, Funakoshi Y, Imamura Y, Toyoda M, Shimada T, Tomioka H, Yakushijin K, Okamura A, Matsuoka H, Minami H. Pathophysiological Role of Cachexia in Patients with Advanced Pancreatic Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32343-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
23
|
Shimada T, Kiyota N, Fujiwara Y, Nishimura M, Imamura Y, Funakoshi Y, Tomioka H, Toyoda M, Chayahara N, Yakushijinn K, Okamura A, Mukohara T, Matsuoka H, Minami H. Retrospective Analysis of Cancer-Related Venous Thromboembolism (VTE) at a Single Institution. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32526-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
24
|
Imamura Y, Fujiwara Y, Toyoda M, Chyayahara N, Nishimura M, Funakoshi Y, Tomioka H, Shimada T, Yakushijin K, Okamura A, Kiyota N, Mukohara T, Matsuoka H, Minami H. Dacarbazine Mono-Therapy for Unresectable Neuroendocrine Tumor: A Retrospective Analysis. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32511-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
25
|
Tatano Y, Sano C, Emori M, Saito H, Sato K, Shimizu T, Tomioka H. [Phagocytosis of Mycobacterium leprae down-regulates anti-microbial activity of murine macrophages against Mycobacterium intracellulare]. Nihon Hansenbyo Gakkai Zasshi 2012; 81:175-83. [PMID: 23012845 DOI: 10.5025/hansen.81.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Patients with highly bacillated lepromatous leprosy (LL) essentially lack T cell-mediated immune responses specific to Mycobacterium leprae (ML) antigens, resulting in severely impaired host resistance to leprosy bacilli. Such type of immune unresponsiveness characteristic of LL patients is mainly attributable to markedly depressed T cell ability to activate/expand in response to ML antigens. In this study, we examined profiles of antimycobacterial activity of macrophages, which phagocytized leprosy bacilli, because there is another possibility that, in LL patients, host macrophages in the leprosy lesions are impaired in their antimicrobial activity due to their interaction with infected leprosy bacilli, particularly cellular events through binding with and/or internalization of the pathogens, thereby causing the reduction in host resistance to ML pathogens. The present study indicated the following. First, the anti-M. avium complex activity of murine peritoneal macrophages was significantly reduced when they had phagocytosed heat-killed leprosy bacilli. Second, infection of macrophages with leprosy bacilli did not affect macrophage-mediated suppressor activity against T cell proliferative response to Concanavalin A. These findings indicate that macrophage's intracellular signaling pathways that are up-regulated in response to phagocytosis of leprosy bacilli are linked to the signaling cascades participating in macrophage antimicrobial functions, but not cross-talk with those allowing the expression of macrophage's suppressor activity against T cell functions.
Collapse
Affiliation(s)
- Yutaka Tatano
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane, Japan
| | | | | | | | | | | | | |
Collapse
|
26
|
Sano C, Tatano Y, Shimizu T, Yamabe S, Sato K, Tomioka H. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium. Int J Antimicrob Agents 2011; 37:296-301. [DOI: 10.1016/j.ijantimicag.2010.12.014] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2010] [Revised: 11/22/2010] [Accepted: 12/21/2010] [Indexed: 10/18/2022]
|
27
|
Tomioka H, Tatano Y, Sano C, Shimizu T. Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks. J Infect Chemother 2011; 17:302-17. [PMID: 21243398 DOI: 10.1007/s10156-010-0177-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2010] [Indexed: 12/27/2022]
Abstract
The worldwide increase in the prevalence of tuberculosis (TB), especially multidrug-resistant TB and extensively drug-resistant TB, is an important global health concern, and new effective drugs are urgently needed. Information on the genome of Mycobacterium tuberculosis (MTB) and various mycobacterial virulence genes is leading to the identification of genes that code for new drug targets. Mycobacterium tuberculosis (MTB) is resistant to the antimicrobial mechanisms of host macrophages and can survive and replicate in macrophages for long periods, resulting in a persistent infection. Mycobacterial virulence factors suppress macrophage bactericidal functions partly via their downregulatory effects on the host antimicrobial cytokine networks, consisting of proinflammatory, immunopotentiating, and Th1-inducing cytokines. Thus, for the development of unique drugs that exhibit antimycobacterial action through novel mechanisms, it is reasonable to search for targets among bacterial genes encoding virulence factors which interfere with the host cytokine responses protective to mycobacterial pathogens. In this review, we discuss the profiles of cytokine networks related to host resistance to mycobacteria, including the mechanisms of downregulation of host antimycobacterial immunity due to immunosuppressive cytokines, which are occasionally induced in the advanced stages of TB. We also highlight the development of antituberculous drugs based on bacterial virulence factors interfering with the host antimycobacterial cytokine network.
Collapse
Affiliation(s)
- Haruaki Tomioka
- Department of Microbiology and Immunology, Faculty of Medicine, Shimane University, Izumo, Shimane 693-8501, Japan.
| | | | | | | |
Collapse
|
28
|
Tomioka H. [Prospects for the development of new antituberculous drugs putting our hopes on new drug targets]. Kekkaku 2010; 85:815-822. [PMID: 21174739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Worldwide, tuberculosis remains the most frequent and important infectious disease to cause morbidity and death. However, the development of new drugs for the treatment and prophylaxis of TB has been slow. Therefore, novel types of antituberculous drugs, which act on the unique drug targets in Mycobacterium tuberculosis, particularly the drug targets related to the establishment of mycobacterial dormancy in host's macrophages, are urgently needed. In this context, it should be noted that current antituberculous drugs mostly target the metabolic reactions and proteins which are essential for the growth of M. tuberculosis in extracellular milieus. It may also be promising to develop another type of drug that exerts an inhibitory action against bacterial virulence factors which cross talk and interfere with signaling pathways of M. tuberculosis-infected host immunocompetent cells such as lymphocytes, macrophages and NK cells, thereby changing the intracellular milieus favorable to intramacrophage survival and growth of infected bacilli. In this review article, I will describe recent approaches to identify and establish novel potential drug targets in M. tuberculosis, especially those related to mycobacterial virulence, dormancy, and cross-talk with cellular signaling pathways.
Collapse
Affiliation(s)
- Haruaki Tomioka
- Department of Microbiology and Immunology, Shimane University School of Medicine, 89-1, Enyacho, Izumo-shi, Shimane 693-8501, Japan.
| |
Collapse
|
29
|
Inamasu J, Miyatake S, Tomioka H, Shirai T, Ishiyama M, Komagamine J, Kase K, Kobayashi K. Prognostic significance of acute pain preceding out-of-hospital cardiac arrest. Emerg Med J 2010; 28:613-7. [DOI: 10.1136/emj.2009.084269] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Tatano Y, Yasumoto K, Shimizu T, Sano C, Sato K, Yano S, Takeyama H, Tomioka H. Comparative study for the virulence of Mycobacterium avium isolates from patients with nodular-bronchiectasis- and cavitary-type diseases. Eur J Clin Microbiol Infect Dis 2010; 29:801-6. [DOI: 10.1007/s10096-010-0930-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2009] [Accepted: 04/03/2010] [Indexed: 11/30/2022]
|
31
|
Shimizu T, Yasumoto K, Tatano Y, Tomioka H, Sato K, Sano C, Kumon H, Monden K. In vitro drug susceptibility of Mycobacterium bovis BCG Connaught and Tokyo strains. J Infect 2010; 60:248-51. [DOI: 10.1016/j.jinf.2010.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2009] [Revised: 01/07/2010] [Accepted: 01/07/2010] [Indexed: 11/28/2022]
|
32
|
Tomioka H, Tada A. [Can we have adequate chemotherapy regimens for tuberculosis in the future? Current status and future prospects for development of new antituberculosis drugs]. Kekkaku 2010; 85:113-123. [PMID: 20373546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
|
33
|
Tatano Y, Shimizu T, Tomioka H. Properties of immunosuppressive macrophages generated by Mycobacterium intracellulare infection in M. intracellulare-susceptible and resistant mice. New Microbiol 2010; 33:87-91. [PMID: 20402419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Splenic macrophages (M(phi)s) generated in Mycobacterium intracellulare (Min)-infected mice exhibit suppressor activity against T cell mitogenesis. We examined profiles of the Min-induced generation of immunosuppressive M(phi)s (Min-M(phi)s) in Min-susceptible BALB/c (bcg(s)) and resistant CBA/JN (bcg(r)) mice. Min infection in BALB/c mice caused a more rapid generation of the immunosuppressive M(phi)s, which expressed M(phi) markers such as CD11b and F4/80, exhibited an increased ability to generate reactive oxygen intermediates, and inhibited IL-2 receptor expression by mitogenic T cells, than did Min infection in CBA/JN mice. Thus, the bcg gene may be related to the generation of Min-M(phi)s in host mice.
Collapse
Affiliation(s)
- Yutaka Tatano
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Japan
| | | | | |
Collapse
|
34
|
Henmi M, Fusaoka Y, Tomioka H, Kurihara M. High performance RO membranes for desalination and wastewater reclamation and their operation results. Water Sci Technol 2010; 62:2134-2140. [PMID: 21045342 DOI: 10.2166/wst.2010.396] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Reverse osmosis (RO) membrane is one of the most powerful tools for solving the global water crisis, and is used in a variety of water treatment scenes such as drinking water purification, waste-water treatment, boiler feed water production, ultra pure water production for semiconductor industry, etc. The desired performance of RO membrane varies according to quality of feed water being treated, and Toray has been developing RO membranes with suitable characteristic for each operating condition. RO membranes for seawater desalination and wastewater reclamation are especially regarded as most promising targets. Recently, high boron removal and energy saving RO membrane for seawater desalination and low fouling RO membrane for wastewater reclamation have been developed. In this paper, the prospect of attaining these renovative RO membrane, and furthermore, job references will be discussed.
Collapse
Affiliation(s)
- M Henmi
- Toray Industries, Inc., 3-2-1 Sonoyama, Otsu, Shiga 520-0842, Japan.
| | | | | | | |
Collapse
|
35
|
Abstract
Macrophages (M(phi)s) play a central role as anti-microbial effector cells in the expression of host resistance to mycobacterial infections. With respect to antimicrobial effector molecules of host M(phi) against mycobacterial pathogens, recent studies suggest the possibility that the reactive nitrogen intermediates (RNI)--and reactive oxygen intermediates-independent antimycobacterial mechanism(s) may be crucial for the antimycobacterial function of host M(phi). In this context, we previously found that free fatty acids (FFAs) such as arachidonic acid (AA) and linolenic acid exhibited potent antimicrobial activity against mycobacterial organisms, including Mycobacterium tuberculosis (MTB) and Mycobacterium avium complex (MAC). In addition, FFAs in combination with RNI played critical roles in manifestation of the activity of M(phi) against mycobacterial organisms. Moreover, our recent studies have shown the following findings. First, anti-MTB activity of IFN-gamma-activated M(phi)s was specifically blocked by arachidonyl trifluoromethylketone (aTFMK), an inhibitor of cytosolic phospholipase A2 (cPLA2). Second, ATP potentiated the anti-MAC bactericidal activity of M(phi)s cultivated in the presence of clarithromycin and rifamycin. This effect of ATP was closely related to intracellular Ca2+ mobilization and was specifically blocked by aTFMK. Third, intramacrophage translocation of membranous AA molecules to MAC-containing phagosomes was also specifically blocked by aTFMK. In the confocal microscopic observation of MAC-infected M(phi)s, ATP enhanced the intracellular translocation of cPLA2 into MAC-containing phagosomes. These findings suggest that FFAs (especially AA) produced by the enzymatic action of cPLA2 play important roles as antimycobacterial effectors in the expression of M(phi) antimicrobial activity against mycobacterial pathogens.
Collapse
Affiliation(s)
- Toshiaki Shimizu
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane, Japan
| | | |
Collapse
|
36
|
Yamanaka K, Yamagata B, Tomioka H, Kawasaki S, Mimura M. Transcranial Magnetic Stimulation of the Parietal Cortex Facilitates Spatial Working Memory: Near-Infrared Spectroscopy Study. Cereb Cortex 2009; 20:1037-45. [DOI: 10.1093/cercor/bhp163] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Yamanaka K, Yamagata B, Noda Y, Tomioka H, Kobayashi H, Isomura A, Mimura M. Hemisphere Asymmetrical Transcranial Magnetic Stimulation Effect on Parietal Cortex, Detected with Near Infrared Spectroscopy; Facilitation of spatial working memory task relevant with visuospatial attention task. Neuroimage 2009. [DOI: 10.1016/s1053-8119(09)70993-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
38
|
Tomioka H. [Immuno-adjuvants for the treatment of MAC infection]. Jpn J Antibiot 2009; 62 Suppl A:33-43. [PMID: 22452053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
|
39
|
Morishita A, Hoshino K, Katahira S, Tomioka H. [Effectiveness of high frequency jet ventilation introduced immediately after cardiac surgery]. Kyobu Geka 2008; 61:1039-1042. [PMID: 19048904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
It is important to establish the lung protective strategy strictly for serious respiratory failure after cardiac surgery, because the hemodynamic state is unstable. High frequency jet ventilation (HFJV) was introduced in 5 patients with respiratory failure after cardiac surgery. Two had been diagnosed with acute aortic dissection and 3 with angina pectorlis. Off pump coronary artery bypass grafting was performed in 2 patients. Hemodynamic variables during HFJV were stable, and the duration of HFJV was 9 to 45 hours. Oxygenations improved immediately by the introduction of HFJV in all patients, and no adverse effect was recognized. Therefore, use of HFJV immediately after cardiac surgery might be an effective respiratory therapy of choice for patients with acute lung injury.
Collapse
Affiliation(s)
- A Morishita
- Department of Cardiovascular Surgery, Numata Neurosurgery Heart-Disease Hospital, Numata, Japan
| | | | | | | |
Collapse
|
40
|
Tanaka O, Ohno K, Ohno T, Tomioka H, Shimizu S, Yamagami T, Nishimura T. Should balloon-occluded retrograde transvenous obliteration be the first-line interventional radiologic treatment for bleeding duodenal varices? A case report and review of the literature. Acta Radiol 2008; 49:32-6. [PMID: 17963080 DOI: 10.1080/02841850701633049] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
We report a 78-year-old woman who presented with repeated tarry stools, and having lower duodenal variceal bleeding caused by portal hypertension. Endoscopic therapy had been attempted, but was impossible because the endoscope could not be inserted into the lower duodenum. Thus, the lower duodenal variceal bleeding was treated with balloon-occluded retrograde transvenous obliteration in combination with embolization using microcoils. Complete hemostasis was achieved without complications, and neither the recurrence of varices nor rebleeding has occurred for the last 3 years. A review of the English-language literature reveals only 11 such cases. The world literature is reviewed.
Collapse
Affiliation(s)
- O. Tanaka
- Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Radiology and Department of Gastroenterology, Osaka Railway Hospital, Osaka, Japan
| | - K. Ohno
- Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Radiology and Department of Gastroenterology, Osaka Railway Hospital, Osaka, Japan
| | - T. Ohno
- Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Radiology and Department of Gastroenterology, Osaka Railway Hospital, Osaka, Japan
| | - H. Tomioka
- Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Radiology and Department of Gastroenterology, Osaka Railway Hospital, Osaka, Japan
| | - S. Shimizu
- Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Radiology and Department of Gastroenterology, Osaka Railway Hospital, Osaka, Japan
| | - T. Yamagami
- Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Radiology and Department of Gastroenterology, Osaka Railway Hospital, Osaka, Japan
| | - T. Nishimura
- Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Radiology and Department of Gastroenterology, Osaka Railway Hospital, Osaka, Japan
| |
Collapse
|
41
|
Sano C, Shimizu T, Tatano Y, Yasumoto K, Tomioka H. [Profiles of intracellular expression, distribution, and activation of phospholipase A2 in host macrophages infected with Mycobacterium avium complex]. Kansenshogaku Zasshi 2007; 81:695-9. [PMID: 18095468 DOI: 10.11150/kansenshogakuzasshi1970.81.695] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Our recent studies have shown that type IV cytosolic phospholipase A2 (cPLA2) plays an important role in the expression of macrophage (MPh) antimicrobial activity against the Mycobacterium avium complex (MAC). To clarify the modes of cPLA2 participation in MPh anti-MAC antimicrobial function in detail, we studied intracellular profiles of phospholilase A2, focusing on cPLA2, in MAC-infected MPhs, with the following findings: In murine peritoneal MPhs, cPLA2 was constitutively expressed even in uninfected MPhs, and MAC infection did not increase intramacrophage cPLA2 expression. In an RAW264.7 mouse MPh cell line (RAW264.7 MPhs) infected with MAC, a portion of intracellular cPLA2 was concentrated in MAC organisms residing within MPh phagosomes. MAC infection upregulated intramacrophage cPLA2 expression and induced its phosphorylation. These findings suggest that MAC infection of RAW264.7 MPhs may induce the activation of intracellular cPLA2, translocating it to phagosomes engulfing infected MAC organisms.
Collapse
Affiliation(s)
- Chiaki Sano
- Department of Microbiology and Immunology, Shimane University School of Medicine
| | | | | | | | | |
Collapse
|
42
|
Tomioka H. Development of new antituberculous agents based on new drug targets and structure–activity relationship. Expert Opin Drug Discov 2007; 3:21-49. [DOI: 10.1517/17460441.3.1.21] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
43
|
Tomioka H, Shimizu T, Tatano Y. Effects of picolinic acid on the antimicrobial functions of host macrophages against Mycobacterium avium complex. Int J Antimicrob Agents 2007; 29:460-4. [PMID: 17296287 DOI: 10.1016/j.ijantimicag.2006.12.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2006] [Revised: 12/12/2006] [Accepted: 12/12/2006] [Indexed: 11/29/2022]
Abstract
Picolinic acid (PA) potentiates macrophage (MPhi) antimicrobial activity against intracellular Mycobacterium avium complex (MAC). Here, we studied the mechanisms of this phenomenon using human THP-1 MPhis. First, when PA-treated MAC-infected MPhis were cultured in the presence or absence of reactive oxygen intermediate (ROI) scavengers, nitric oxide synthase (NOS) inhibitors or phospholipase A(2) (PLA(2)) inhibitors, none of these agents blocked the activity of PA in potentiating MPhi anti-MAC activity. Second, when PA was added to the in vitro anti-MAC bactericidal system consisting of either ROIs, reactive nitrogen intermediates (RNIs) or free fatty acid (FFA) molecules, which are the major MPhi antimicrobial effectors, PA inhibited the activity of ROIs and conversely potentiated the activity of RNIs; PA did not affect the activity of FFAs. Third, PA reduced mRNA expression of NADPH oxidase and beta-defensin-1 by MAC-infected MPhis, whilst neither cytosolic PLA(2) nor CAP37 mRNA expression was affected. Notably, inducible NOS and secretory PLA(2) mRNA expression was not detected for MAC-infected MPhis even when given PA treatment. These findings suggest that ROIs, RNIs, FFAs and beta-defensin-1 do not play important roles in the PA-induced potentiation of MPhi anti-MAC activity.
Collapse
Affiliation(s)
- Haruaki Tomioka
- Department of Microbiology and Immunology, Shimane University School of Medicine, Enya-cho 89-1, Izumo, Shimane 693-8501, Japan.
| | | | | |
Collapse
|
44
|
Tomioka H, Namba K. [Development of antituberculous drugs: current status and future prospects]. Kekkaku 2006; 81:753-74. [PMID: 17240921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Worldwide, tuberculosis (TB) remains the most frequent and important infectious disease causing morbidity and death. One-third of the world's population is infected with Mycobacterium tuberculosis (MTB), the etiologic agent of TB. The World Health Organization estimates that about eight to ten million new TB cases occur annually worldwide and the incidence of TB is currently increasing. In this context, TB is in the top three, with malaria and HIV being the leading causes of death from a single infectious agent, and approximately two million deaths are attributable to TB annually. In particular, pulmonary TB, the most common form of TB, is a highly contagious and life-threatening infection. Moreover, enhanced susceptibility to TB in HIV-infected populations is another serious health problem throughout the world. In addition, multidrug-resistant TB (MDR-TB) has been increasing in incidence in many areas, not only in developing countries but industrialized countries as well, during the past decade. These situations, particularly the global resurgence of TB and the rapid emergence of MDR-TB, underscore the importance of the development of new antituberculous drugs and new protocols for efficacious clinical control of TB patients using ordinary antimycobacterial drugs. Concerning the development of new antituberculous drugs, the following points are of particular importance. (1) Development of drugs which display lasting antimycobacterial activity in vivo is desirable, since they can be administered with long intervals and consequently facilitate directly observed therapy and enhance patient compliance. (2) Development of novel antituberculosis compounds to combat MDR-TB is urgently needed. (3) The eradication of slowly metabolizing and, if possible, dormant populations of MTB organisms that cause relapse, using new classes of anti-TB drugs is very promising for prevention of TB incidence, because it will markedly reduce the incidence of active TB from persons who are latently infected with MTB. Unfortunately, no new drugs except rifabutin and rifapentine has been marketed for TB in the US and other countries during the 40 years after release of rifampicin. There are a number of constraints that have deterred companies from investing in new anti-TB drugs. The research is expensive, slow and difficult, and requires specialized facilities for handling MTB. There are few animal models that closely mimic the human TB disease. Development time of any anti-TB drug will be long. In fact, clinical trials will require the minimum six-month therapy, with a follow-up period of one year or more. In addition, it is hard to demonstrate obvious benefit of a new anti-TB agents over pre-existing drugs, since clinical trials involve multidrug combination therapy using highly effective ordinary anti-TB drugs. Finaly, there is the perceived lack of commercial return to companies engaged in the development of new anti-TB drugs, because over 95% of TB cases worldwide are in developing countries. In this symposium, we reviewed the following areas. 1. Critical new information on the entire genome of MTB recently obtained and increasing knowledge of various mycobacterial virulence genes are greatly promoting the identification of genes that code for new drug targets. In this context, Dr. Namba reviewed the status of new types of compounds which are being developed as anti-TB drug. He also discussed the development of new antimycobacterial drugs according to new and potential pharmacological targets and the best clinical development plans for new-TB drugs in relation to corporate strategy. 2. Using such findings for mycobacterial genomes, bioinformatics/genomics/proteomics-based drug design and drug development using quantitative structure-activity relationships may be possible in the near future. In this context, Dr. Suwa and Dr. Suzuki reviewed the usefulness of chemical genomics in searching novel drug targets for development of new antituberculous drugs. The authors reviewed (1) the history and present status of chemical genomics that is defined as the systemic search for a selective small molecular modulator for each function of all gene products, (2) recent studies of the authors on profiles of the interactions between various kinds of human proteins and small molecule modulators using the new technology devised by Reverse Proteomics Research Institute, and (3) future prospects of the development of new antituberculous drugs based on chemical genomics. 3. It appears also promising to develop new types of drug administration systems using drug vehicles, which enable efficacious drug delivery to their target in vivo. Dr. Izumikawa, Dr. Ohno and Dr. Kohno reviewed the usefulness of liposome- and polymer-based technologies, which enable efficacious delivery of encapsulated drugs at required doses for prolonged periods of time with only a single shot without toxicity, and also enable highly targeted delivery of drugs to their target in vivo. They indicated that the applications of drug delivery system using conventional anti-mycobacterial agents are challenging to improve the compliance of treatment and better clinical outcome. 4. Immunoadjunctive therapy appears to be promising in improving outcome of clinical control of refractory mycobacterial infections, including MDR-TB and M. avium complex infection. Dr. Shimizu, Dr. Sato and Dr. Tomioka reviewed the present status of immunotherapy of mycobacterial infections in combination with antimycobacterial drugs. They indicated that the development of new classes of immunomodulators other than cytokines (IL-2, IFN-gamma, GM-CSF, IL-12, etc.) particularly those with no severe side-effects, are urgently needed. Their review dealed with some promising immunoadjunctive agents, especially ATP and its analogues, which potentiate macrophage antimycobacterial activity via purinergic P2 receptors. The aim of this symposium is to address the future prospects of the development of new drugs and drug regimens for anti-TB chemotherapy. There are a number of difficulties in drug-design for the development of new drug formulations with increased potential for antimycobacterial effects, excellent pharmacokinetics, and tolerability. It should be emphasized that the most urgent goal of chemotherapy of TB and MAC infections, especially that associated with HIV infection, is to develop highly active, low-cost drugs which can be used not only in industrialized countries but also in developing countries, since the incidences of AIDS-associated intractable TB and MAC infections are rapidly increasing in the latter. We strongly wish a great advance of fundametal and practical studies in developing such kinds of new anti-TB drugs in the near future. 1. Prospects for non-clinical or clinical development of new antituberculous drugs in relation to corporate strategy: Kenji NAMBA (New Product Research Laboratories I, Daiichi Pharmaceutical Co., Ltd.) Tuberculosis (TB) remains one of the deadliest threats to public health. No new anti-TB drugs have been brought into the clinic in the past 40 years. Current non-clinical works with progressed technology and Global Alliance for TB Drug Development, a non-profit organization established in 2000, accelerate research and development of faster-acting anti-TB compounds. We reviewed the status of new types of compounds which are being developed as anti-TB drug, such as diarylquinoline (TMC 207), nitroimidazole (PA-824 and OPC-67683), and moxifloxacin (MFLX). We also discussed the best clinical development plans for new-TB drugs in relation to corporate strategy. 2. Exploring novel drug targets through the chemical genomics approach and its possible application to the development of anti-tuberculosis drugs: Yorimasa SUWA (Reverse Proteomics Research Institute Co., Ltd.), Yohji SUZUKI (Teijin Ltd.) Recently, chemical genomics approach has been focused as an emerging technology for the drug discovery. In advance to a very large scale national project in US started last year, Reverse Proteomics Research Institute Co., Ltd. (REPRORI) has developed the core technologies for chemical genomics. Here we describe the outline of chemical genomics study, especially that of REPRORI, and discuss about its possible application to the development of anti-tuberculosis drugs. 3. Anti-mycobacterial agents and drug delivery: Koichi IZUMIKAWA, Hideaki OHNO, Shigeru KOHNO (Second Department of Internal Medicine, Nagasaki University School of Medicine) Mycobacterium infection is a major clinical concern in whole world. Since the newly developed anti-mycobacterial agents are few and still unavailable in clinical settings, the applications of drug delivery system using conventional anti-mycobacterial agents are challenging to improve the compliance of treatment and better efficacy. The efficacy of anti-mycobacterial agents modified by liposome or polymer based technology have been investigated and reported using various animal models. Drug delivery system increased and prolonged the drug concentrations at the blood and targeted organs and the duration of sustained drug release, respectively. These effects lead to decrease in the frequency of drug administrations dramatically and better efficacy rates. The studies, however, were performed only in animal models, the further investigations and evaluations in human are required for practical use. 4. Adjunctive immunotherapy of mycobacterial infections: Toshiaki SHIMIZU, Katsumasa SATO, Haruaki TOMIOKA (Department of Microbiology and Immunology, Shimane University School of Medicine) There is an urgent need to develop new antimicrobials and protocols for the administration of drugs that are potently efficacious against intractable mycobacterial infections. Unfortunately, development of the new drugs for solving this problem is not progressing. (ABSTRACT TRUNCATED)
Collapse
Affiliation(s)
- Haruaki Tomioka
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo-Shi, Japan.
| | | |
Collapse
|
45
|
Shimizu T, Tomioka H. Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex. Antimicrob Agents Chemother 2006; 50:3186-8. [PMID: 16940126 PMCID: PMC1563513 DOI: 10.1128/aac.01510-05] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
We studied the in vitro and in vivo antimicrobial activities of picolinic acid (PA) in combination with the antiprotozoal drug quinacrine against intramacrophage Mycobacterium avium complex (MAC). Quinacrine significantly potentiated the anti-MAC activity of PA, suggesting the usefulness of this combination in the clinical control of MAC infection.
Collapse
Affiliation(s)
- Toshiaki Shimizu
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693-8501, Japan
| | | |
Collapse
|
46
|
Tomioka H. Current Status of Some Antituberculosis Drugs and the Development of new Antituberculous Agents with Special Reference to their In Vitro and In Vivo Antimicrobial Activities. Curr Pharm Des 2006; 12:4047-70. [PMID: 17100611 DOI: 10.2174/138161206778743646] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Tuberculosis (TB) is a growing international health concern, since it is the leading infectious cause of death in the world today. In particular, the increasing prevalence of multidrug-resistant (MDR)-TB has greatly contributed to the increased difficulties in the control of TB. Because of the global health problems of TB, the increasing rate of MDR-TB and the high rate of a co-infection with HIV, the development of potent new anti-TB drugs without cross-resistance with known antimycobacterial agents is urgently needed. This article deals with the following areas. First, it briefly reviews some recent findings on the pharmacological status of fluoroquinolones and rifamycin derivatives. Second, it describes other types of new agents, such as oxazolidinones (linezolid, PNU-100480), nitroimidazoles (nitroimidazopyran PA-824, metronidazole), 2-pyridone, riminophenazines and diarylquinolines, which are being developed as anti-TB drugs. In addition, the future development of new antitubercular drugs is briefly discussed according to the potential pharmacological targets. New critical information on the whole genome of Mycobacterium tuberculosis (MTB) was recently elucidated and increasing knowledge on various mycobacterial virulence genes will promote the progression in the identification of genes that code for new drug targets. Using such findings on MTB genome, drug development using quantitative structure-activity relationship may be possible in the near future.
Collapse
Affiliation(s)
- Haruaki Tomioka
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693-8501, Japan.
| |
Collapse
|
47
|
Ueo T, Yazumi S, Okuyama S, Okada Y, Oono T, Watanabe M, Umehara Y, Honjo H, Mitumoto Y, Mori T, Tomioka H, Mugitani T, Mizuno S, Chiba T, Shimizu S. Acute cholecystitis due to strangulation of a floating gallbladder by the lesser omentum. Abdom Imaging 2006; 32:348-50. [PMID: 16897276 DOI: 10.1007/s00261-006-9026-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We report a unique case of acute cholecystitis due to strangulation of a floating gallbladder by the lesser omentum, which could be detected by abdominal ultrasonography. We believe this case to be the first case of reported literatures in English.
Collapse
Affiliation(s)
- T Ueo
- Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, 54 Shogoin- Kyoto 606-8507, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Cai S, Shimizu T, Tomioka H. Comparative studies on the roles of mediator molecules in expression of the suppressor activity of Mycobacterium avium complex-induced immunosuppressive macrophages against T cell and B cell mitogenic responses. Clin Exp Immunol 2006; 143:560-71. [PMID: 16487256 PMCID: PMC1809612 DOI: 10.1111/j.1365-2249.2006.03016.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Mycobacterium avium complex-induced immunosuppressive macrophages (MAC-MPhis) exhibit suppressor activity against concanavalin A-induced T cell mitogenesis (T cell Con A mitogenesis). We examined the profiles of the MAC-MPhi-mediated suppression of lipopolysaccharide-induced B cell mitogenesis (B cell LPS mitogenesis) and found the following. First, although N(G)-monomethyl-L-arginine and carboxy-PTIO effectively blocked the MAC-MPhi's suppressor activity against T cell Con A mitogenesis, MAC-MPhi's action against B cell LPS mitogenesis was only weakly affected by these NO-reducing agents. Second, B cell LPS mitogenesis was remarkably more susceptible to MAC-MPhi-derived reactive oxygen intermediates than T cell Con A mitogenesis. Third, B cell LPS mitogenesis was less susceptible to the inhibitory effects of the other MAC-MPhi-derived suppressor mediators, including free fatty acids, TGF-beta and prostaglandin E(2), than T cell Con A mitogenesis. Fourth, MAC-MPhi's suppressor activity was strongly dependent on B7-1 like molecule-mediated cell contact with target cells only in the case of T cell Con A mitogenesis. Therefore, there are significant differences in the modes of suppressor action of MAC-MPhis against T cell and B cell mitogenesis.
Collapse
Affiliation(s)
- S Cai
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Shimane 693-8501, Japan
| | | | | |
Collapse
|
49
|
Sato K, Shimizu T, Sano C, Tomioka H. Effects of type II alveolar epithelial cells on T cell mitogenic responses to concanavalin A and purified protein derivatives. Microbiol Immunol 2006; 49:885-90. [PMID: 16237265 DOI: 10.1111/j.1348-0421.2005.tb03679.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
To investigate the role of type II alveolar epithelial cells during the T cell-dependent host immune response to Mycobacterium tuberculosis (MTB), effects of MTB-infected A-549 human type II alveolar epithelial cells (A-549 cells) on T cell mitogenesis in response to concanavalin A (Con A) and purified protein derivatives (PPD) were studied. Human peripheral blood mononuclear cells (PBMCs) were cocultivated with uninfected or MTB-infected A-549 cells and Con A-and PPD-induced T cell mitogeneses were examined, and the following findings were obtained. T cell mitogenesis was inhibited by uninfected as well as MTB-infected A-549 cells, even when a dual-chamber culture system was used to prevent direct cell contact between PBMCs and A-549 cells. Therefore, it appears that A-549 cells suppress T cell mitogenesis by producing some unknown humoral suppressor factors.
Collapse
Affiliation(s)
- Katsumasa Sato
- Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo, Japan
| | | | | | | |
Collapse
|
50
|
Tomioka H, Sano C, Sato K, Ogasawara K, Akaki T, Sano K, Cai SS, Shimizu T. Combined effects of ATP on the therapeutic efficacy of antimicrobial drug regimens against Mycobacterium avium complex infection in mice and roles of cytosolic phospholipase A2-dependent mechanisms in the ATP-mediated potentiation of antimycobacterial host resistance. J Immunol 2006; 175:6741-9. [PMID: 16272330 DOI: 10.4049/jimmunol.175.10.6741] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
ATP, which serves as a mediator of intramacrophage signaling pathways through purinoceptors, is known to potentiate macrophage antimycobacterial activity. In this study we examined the effects of ATP in potentiating host resistance to Mycobacterium avium complex (MAC) infection in mice undergoing treatment with a drug regimen using clarithromycin and rifamycin and obtained the following findings. First, the administration of ATP in combination with the clarithromycin and rifamycin regimen accelerated bacterial elimination in MAC-infected mice without causing changes in the histopathological features or the mRNA expression of pro- or anti-inflammatory cytokines from those in the mice not given ATP. Second, ATP potentiated the anti-MAC bactericidal activity of macrophages cultivated in the presence of clarithromycin and rifamycin. This effect of ATP was closely related to intracellular Ca2+ mobilization and was specifically blocked by a cytosolic phospholipase A2 (cPLA2) inhibitor, arachidonyl trifluoromethylketone. Third, intramacrophage translocation of membranous arachidonic acid molecules to MAC-containing phagosomes was also specifically blocked by arachidonyl trifluoromethylketone. In the confocal microscopic observation of MAC-infected macrophages, ATP enhanced the intracellular translocation of cPLA2 into MAC-containing phagosomes. These findings suggest that ATP increases the host anti-MAC resistance by potentiating the antimycobacterial activity of host macrophages and that the cPLA2-dependent generation of arachidonic acid from the phagosomal membrane is essential for such a phenomenon.
Collapse
Affiliation(s)
- Haruaki Tomioka
- Department of Microbiology and Immunology, Shimane University School of Medicine, Shimane, Japan.
| | | | | | | | | | | | | | | |
Collapse
|